SCHEMBL4868895

SCHEMBL4868895

O=C(CCl)c1cccc(C(F)(F)F)c1F

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.48
KAT6A Q92794 2/20 0.46
YAP1 P46937 1/20 0.46
TEAD4 Q15561 1/20 0.46
TEAD2 Q15562 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
CTNNB1 P35222 3/20 0.42
WNT3A P56704 3/20 0.42
P2RX7 Q99572 4/20 0.42
EPHX2 P34913 2/20 0.41
GSK3B P49841 1/20 0.41
HDAC8 Q9BY41 1/20 0.40
CD38 P28907 1/20 0.39
CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358195 0.84 CTNNB1 (0.57) YAP1TEAD4TEAD2LMNAGAA
SCHEMBL1198865 0.83 CTSS (0.48) CTSSKAT6ATAS1R3TAS1R1TAS1R2
SCHEMBL5375712 0.83 YAP1 (0.46) CTSSYAP1TEAD4TEAD2LMNA
SCHEMBL4873112 0.83 CTSS (0.55) CTSSKAT6ATAS1R3TAS1R1TAS1R2
SCHEMBL283643 0.80 KAT6A (0.49) CTSSKAT6ATAS1R3TAS1R1TAS1R2
SCHEMBL28188796 0.80 KAT6A (0.51) CTSSKAT6ATAS1R3TAS1R1TAS1R2
SCHEMBL398909 0.78 KAT6A (0.54) CTSSKAT6ATAS1R3TAS1R1TAS1R2
SCHEMBL9560994 0.78 KAT6A (0.50) CTSSKAT6ATAS1R3TAS1R1TAS1R2
SCHEMBL5365219 0.78 GSK3B (0.46) CTSSYAP1TEAD4TEAD2LMNA
SCHEMBL3058748 0.78 CES2 (0.61) KAT6AYAP1TEAD4TEAD2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102573994-B Novel bicyclic urea compounds MERCK PATENT GMBH 2015-06-24 CN disclosed
US-20080076771-A1 Thrombopoietin Receptor Agonists REITER LAWRENCE A 2008-03-27 US disclosed
EP-1794156-A2 TROMBOPOIETIN RECEPTOR AGONISTS Pfizer Products Incorporated (US) 2007-06-13 EP disclosed
WO-2006033005-A2 THROMBOPOIETIN RECEPTOR AGONISTS PFIZER PRODUCTS INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076771-A1 Thrombopoietin Receptor Agonists MPL, THPO, TBXA2R CTSS 3979/4885KAT6A 3796/4885YAP1 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.